Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOXIRI and Chemoradiation in High Risk Rectal Cancer
NCT01941641Phase 2Active, not recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2013
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan in rectal cancer, sponsored by The Chinese University of Hong Kong. Started Oct 2013; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01941641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941641.